REDWOOD CITY, Calif.,
May 7, 2015 /PRNewswire/ -- Genomic
Health, Inc. (Nasdaq: GHDX) today announced that results from five
studies will be presented at the American Urological Association
Annual Meeting, which will take place May
15-19 at the New Orleans Ernest N. Morial Convention Center.
Poster discussions will include studies supporting wider adoption
and reimbursement of the Oncotype DX® prostate cancer test and
positive results from an expanded feasibility study in bladder
cancer, demonstrating the company's progress in developing a
urine-based liquid biopsy test to monitor cancer recurrence.
"These scientific presentations reflect our successful efforts
to build the clinical evidence supporting widespread adoption and
reimbursement of our prostate cancer test and begin to describe our
new platform of non-invasive tests aimed at individualizing cancer
care throughout a patient's journey," said Phil Febbo, M.D., chief medical officer, Genomic
Health.
Results of the studies will be presented as follows (all times
are Central Daylight Time) and abstracts are now available at
http://www.aua2015.org/abstracts:
Friday, May 15
- Title: "The 17-gene Genomic Prostate Score (GPS) Assay:
Initial Clinical Experience of 4,000 Patients" (Abstract:
MP1-01)
Authors: Katz A, Ho A, Burke E, Denes B, Lu R, Rothney M,
Bonham M, Tsiatis A, Lawrence J, Febbo P.
Location: NOMCC 220-221
Time: 10:30 a.m. –
12:30 p.m.
- Title: "A Multi-center Comparison of a 17-gene Genomic
Prostate Score (GPS) as a Predictor of Outcomes in African-American
(AA) and Caucasian (CA) Men with Clinically Localized Prostate
Cancer (PCa)" (Abstract: MP1-05)
Authors: Cullen J, Sesterhenn I, Klein E, Mohler J, Carroll
P, Cooperberg M, Zhang N, Maddala T, Knezevic D, Tsiatis A,
Lawrence HJ, Febbo P.
Location: NOMCC 220-221
Time: 10:30 a.m. –
12:30 p.m.
- Title: "Clinical Benefits and Costs of a 17-gene Assay
Designed to Assess Disease-Progression Risk after Positive Prostate
Cancer Biopsy" (Abstract: MP1-06)
Authors: Dall'Era M, Michalopoulos SN, Denes BS, Tighe J,
Hornberger J.
Location: NOMCC 220-221
Time: 10:30 a.m. –
12:30 p.m.
Sunday, May 17
- Title: "Comparison of Different Analytical Platforms for
the Identification of Tumor DNA in the Urine of Bladder Cancer
Patients" (Abstract: MP45-14)
Authors: Resnick MJ, Abramson RD, Yoshizawa C, Lam PN, Shore
N, Tezcan H.
Location: NOMCC 243-245
Time: 10:30 a.m. –
12:30 p.m.
- Title: "Association Between a 17-gene Genomic Prostate
Score and Multi-Parametric Prostate MRI in Men with Low and
Intermediate Risk Prostate Cancer (PCa)" (Abstract: MP53-18)
Authors: Leapman M, Westphalen A, Ameli N, Lawrence J, Febbo
P, Cooperberg M, Carroll P.
Location: NOMCC 211-213
Time: 1 – 3 p.m.
About Oncotype DX
The Oncotype DX® portfolio of breast, colon and prostate
cancer tests applies advanced genomic science to reveal the unique
biology of a tumor in order to optimize cancer treatment decisions.
The Oncotype DX prostate cancer test identifies low- to
intermediate-risk patients eligible for active surveillance, as
well as those who may benefit from immediate invasive treatment by
predicting disease aggressiveness. With half a million patients
tested in more than 80 countries, Oncotype DX testing has
redefined personalized medicine by making genomics a critical part
of cancer diagnosis and treatment. To learn more about the
Oncotype DX prostate cancer test,
visit: www.OncotypeDX.com
or www.myprostatecancertreatment.org.
About Genomic Health
Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading
provider of genomic-based diagnostic tests that address both the
overtreatment and optimal treatment of early-stage cancer, one of
the greatest issues in healthcare today. The company is applying
its world-class scientific and commercial expertise and
infrastructure to lead the translation of massive amounts of
genomic data into clinically-actionable results for treatment
planning throughout the cancer patient's journey, from diagnosis to
treatment selection and monitoring. The company is based
in Redwood City, California, with European
headquarters in Geneva, Switzerland. For more
information, please visit, www.GenomicHealth.com and
follow the company on
Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements relating to the belief that the
presentations reflect the company's successful efforts to build
clinical evidence supporting adoption and reimbursement, and the
benefits and attributes of the company's tests or tests in
development, . Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially,
and reported results should not be considered as an indication of
future performance. These risks and uncertainties include, but are
not limited to: the risks and uncertainties associated with
the regulation of the company's tests; the results of clinical
studies; the applicability of clinical study results to actual
outcomes; our ability to develop and commercialize new tests and
expand into new markets domestically and internationally; the risk
that the company may not obtain or maintain sufficient levels of
reimbursement, domestically or abroad, for its existing tests and
any future tests it may develop; the risks of competition;
unanticipated costs or delays in research and development efforts;
the company's ability to obtain capital when needed and the other
risks set forth in the company's filings with the Securities
and Exchange Commission, including the risks set forth in the
company's annual report on Form 10-K for the year
ended December 31, 2014. These forward-looking statements
speak only as of the date hereof. Genomic
Health disclaims any obligation to update these
forward-looking statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype
DX, Recurrence Score, and DCIS Score are trademarks or registered
trademarks of Genomic Health, Inc. All other trademarks
and service marks are the property of their respective
owners.
Logo -
http://photos.prnewswire.com/prnh/20130425/SF01493LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/genomic-health-to-present-multiple-oncotype-dx-studies-and-positive-liquid-biopsy-results-at-american-urological-association-annual-meeting-may-15-19-300078775.html
SOURCE Genomic Health, Inc.